VBI Vaccines Inc. (Nasdaq: VBIV) has announced the availability of PreHevbri® [Hepatitis B vaccine (recombinant, adsorbed)] in the Netherlands and Belgium for active immunization against all known subtypes of the hepatitis B virus (HBV) in adults. The vaccine will be launched in partnership with Valneva, their marketing and distribution partner.
PreHevbri® is currently the only approved 3-antigen hepatitis B vaccine for adults in the Netherlands and Belgium. It is expected to provide protection against hepatitis D as well since hepatitis D cannot occur without a prior hepatitis B infection. Through this collaboration with Valneva, easy access to PreHevbri® will be facilitated through existing commercial infrastructure and distribution networks.
Jeff Baxter, President and CEO of VBI, expressed his excitement about the launch of PreHevbri® in the Netherlands and Belgium. He emphasized their commitment to expanding global access to this vaccine in order to make a significant impact in the fight against hepatitis B worldwide.